Capricor Therap (CAPR)

$28.01 -0.78 (-2.69%)
Market Cap 1.67B
Revenue (ttm) 0.00
Net Income (ttm) -105.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 3,577.21
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 916,700
Avg Vol 1,334,062
Day's Range N/A - N/A
Shares Out 57.91M
Stochastic %K 9%
Beta 0.48
Analysts Strong Sell
Price Target $54.67

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 727 1755
Address:
10865 Road to the Cure, Suite 150, San Diego, United States
Skyhigh77
Skyhigh77 May. 19 at 6:23 AM
$CAPR there’s absolutely no doubt that NS has been behind most of the short positions in this company… they have made a ton of money both ways and now they want to take over Deramiocel.. they came in with bad intentions already in 2022 with Highbridge deal setup to kill of the company but Capricor managed to overcome and succeeded with the P3 stat sig which set of thier newest scam with the ”pricing flaw” which of course they must of known about all along, if they didn’t then I’m a bit worried we chose amateurs as distributors… they even claim the have everything setup already so how was this critical piece missed by such a large company who claims they have experience in distributing in US market?! NS lost the case with the PLD demand and they are scrambling… Capricor will be just fine without NS and even if we are not scaling up like planned it seems we still in a good position going forward… Linda’s fighting spirit makes me calm over my position.. let’s get it
0 · Reply
braindonor
braindonor May. 19 at 5:54 AM
$CAPR $CAPR here’s a good explanation of what NS was up to and why.
1 · Reply
haha1978
haha1978 May. 19 at 2:40 AM
$CAPR where was that loser short who bought puts before the pop to 40? This will be the same scenario longs with actual shares selling puts to broke shorts only able to buy options.
1 · Reply
quito_yume
quito_yume May. 19 at 1:36 AM
$CAPR We are in the final stages of the countdown boys and girls. Don't be surprised to see big announcements this week or next. Don't try to time this one as it could happen any day now, including as early as tomorrow. The MM's are driving the price down for their friends to be able to get in cheap because they know what's coming as well as we do. GLTA!
1 · Reply
hegdaom
hegdaom May. 19 at 1:24 AM
$CAPR
0 · Reply
Weightgainclyde
Weightgainclyde May. 19 at 12:53 AM
$CAPR I’m curious in what other biostocks my fellow CAPR’s invest in. Aside from capr I’m in cadl SLS and ocgn
15 · Reply
dnfrs
dnfrs May. 18 at 11:37 PM
$CAPR Deramiocel will have a powerful effect on the lives of DMD patients. But Capricor has other tools that could be developed using the StealthX exosome platform. https://doaj.org/article/fc20574b01b046f4b63766549f7f01ee?utm_source=copilot.com
0 · Reply
spacecity777
spacecity777 May. 18 at 10:34 PM
$CAPR I spoke to several notable attorney's over the weekend and they both said recission is almost a given. Both parties will be returned to their precontract position. So Capricor will return the milestone payments and Capricor will get 100% of the product rights back. This is absolutely the best situation of all! I think there is a likelihood that NS agrees to this prior to the June 3rd hearing. This is an absolute grand slam event for Capricor shareholders. Sit tight, good days are coming!
7 · Reply
GhostOfFrankie4Fingers
GhostOfFrankie4Fingers May. 18 at 10:23 PM
$CAPR I lost a lot of respect for Martin when he shorted this one, but he still holds a special place in my heart after I banked on the $SAVA short.
2 · Reply
Dash_Man
Dash_Man May. 18 at 10:18 PM
$CAPR AI review of the NS call.
0 · Reply
Latest News on CAPR
Capricor Therapeutics price target lowered to $38 from $43 at Roth Capital

2026-05-15T02:55:10.000Z - 4 days ago

Capricor Therapeutics price target lowered to $38 from $43 at Roth Capital

Capricor Therapeutics Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 6 days ago

Capricor Therapeutics Earnings Call Transcript: Q1 2026

Capricor Therapeutics options imply 9.4% move in share price post-earnings

2026-05-12T20:09:36.000Z - 6 days ago

Capricor Therapeutics options imply 9.4% move in share price post-earnings

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 12, 2026, 4:05 PM EDT - 6 days ago

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Capricor files suit against NS Pharma over Deramiocel distribution deal

2026-05-08T18:58:25.000Z - 10 days ago

Capricor files suit against NS Pharma over Deramiocel distribution deal

Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

May 4, 2026, 4:05 PM EDT - 14 days ago

Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

Capricor Therapeutics price target raised to $43 from $41 at Roth Capital

2026-03-20T12:45:14.000Z - 2 months ago

Capricor Therapeutics price target raised to $43 from $41 at Roth Capital

Capricor selloff today a buying opportunity, says Roth Capital

2026-03-13T18:35:53.000Z - 2 months ago

Capricor selloff today a buying opportunity, says Roth Capital

Capricor Therapeutics price target raised to $51 from $48 at Alliance Global

2026-03-13T16:01:07.000Z - 2 months ago

Capricor Therapeutics price target raised to $51 from $48 at Alliance Global

Capricor Therapeutics price target raised to $63 from $50 at B. Riley

2026-03-13T12:27:39.000Z - 2 months ago

Capricor Therapeutics price target raised to $63 from $50 at B. Riley

Capricor Therapeutics price target raised to $58 from $45 at Piper Sandler

2026-03-13T12:02:13.000Z - 2 months ago

Capricor Therapeutics price target raised to $58 from $45 at Piper Sandler

Capricor Therapeutics Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 2 months ago

Capricor Therapeutics Earnings Call Transcript: Q4 2025

Capricor Therapeutics reports Q4 EPS (62c), consensus (55c)

2026-03-12T20:16:10.000Z - 2 months ago

Capricor Therapeutics reports Q4 EPS (62c), consensus (55c)

Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 12, 2026, 4:01 PM EDT - 2 months ago

Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Capricor Therapeutics options imply 4.2% move in share price post-earnings

2026-03-12T19:16:07.000Z - 2 months ago

Capricor Therapeutics options imply 4.2% move in share price post-earnings

Capricor announces additional analyses, outcomes from Phase 3 HOPE-3 trial

2026-03-12T13:15:17.000Z - 2 months ago

Capricor announces additional analyses, outcomes from Phase 3 HOPE-3 trial

Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy

Mar 12, 2026, 9:00 AM EDT - 2 months ago

Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy

Capricor announces establishment of new PDUFA date for dermiocel BLA

2026-03-10T13:38:59.000Z - 2 months ago

Capricor announces establishment of new PDUFA date for dermiocel BLA

Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA

Mar 10, 2026, 9:25 AM EDT - 2 months ago

Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA

Capricor expects to submit updates to BLA in February 2026

2026-01-20T14:25:31.000Z - 4 months ago

Capricor expects to submit updates to BLA in February 2026

Capricor Therapeutics Transcript: Study Result

Dec 17, 2025, 1:00 PM EST - 5 months ago

Capricor Therapeutics Transcript: Study Result

Capricor Therapeutics price target raised to $50 from $21 at B. Riley

2025-12-15T13:20:28.000Z - 5 months ago

Capricor Therapeutics price target raised to $50 from $21 at B. Riley

Capricor Therapeutics price target raised to $45 from $20 at Piper Sandler

2025-12-10T11:51:19.000Z - 5 months ago

Capricor Therapeutics price target raised to $45 from $20 at Piper Sandler

Capricor Therapeutics management to meet with Oppenheimer

2025-12-08T13:46:18.000Z - 5 months ago

Capricor Therapeutics management to meet with Oppenheimer

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Dec 4, 2025, 4:01 PM EST - 5 months ago

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Capricor Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 11:30 AM EST - 5 months ago

Capricor Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Capricor Therapeutics Transcript: Status Update

Dec 3, 2025, 8:00 AM EST - 5 months ago

Capricor Therapeutics Transcript: Status Update

Capricor's muscle disorder cell therapy succeeds in late-stage study

Dec 3, 2025, 7:44 AM EST - 5 months ago

Capricor's muscle disorder cell therapy succeeds in late-stage study

Capricor Therapeutics Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:30 PM EST - 6 months ago

Capricor Therapeutics Earnings Call Transcript: Q3 2025

Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

Nov 3, 2025, 9:15 AM EST - 7 months ago

Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

Oct 31, 2025, 9:15 AM EDT - 7 months ago

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Oct 3, 2025, 10:45 AM EDT - 8 months ago

Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Capricor Therapeutics Transcript: Study Update

Sep 25, 2025, 8:30 AM EDT - 8 months ago

Capricor Therapeutics Transcript: Study Update

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

Sep 25, 2025, 7:15 AM EDT - 8 months ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

Sep 9, 2025, 9:20 AM EDT - 8 months ago

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

Capricor Therapeutics Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 10 months ago

Capricor Therapeutics Earnings Call Transcript: Q2 2025

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

Aug 8, 2025, 8:30 AM EDT - 10 months ago

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

Aug 6, 2025, 9:00 AM EDT - 10 months ago

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors

Jul 14, 2025, 4:14 PM EDT - 11 months ago

Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors

Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura

Jul 11, 2025, 4:53 PM EDT - 11 months ago

Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura

Capricor Therapeutics Transcript: Study Update

Jul 11, 2025, 8:30 AM EDT - 11 months ago

Capricor Therapeutics Transcript: Study Update

US FDA declines to approve Capricor's muscle disorder therapy

Jul 11, 2025, 6:36 AM EDT - 11 months ago

US FDA declines to approve Capricor's muscle disorder therapy

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

Jul 11, 2025, 6:30 AM EDT - 11 months ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

US FDA will not convene expert panel for Capricor Therapeutics' DMD cell therapy

Jun 24, 2025, 9:16 AM EDT - 11 months ago

US FDA will not convene expert panel for Capricor Therapeutics' DMD cell therapy

Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy

Jun 20, 2025, 9:25 AM EDT - 11 months ago

Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy

Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program

Jun 17, 2025, 9:00 AM EDT - 11 months ago

Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program

Skyhigh77
Skyhigh77 May. 19 at 6:23 AM
$CAPR there’s absolutely no doubt that NS has been behind most of the short positions in this company… they have made a ton of money both ways and now they want to take over Deramiocel.. they came in with bad intentions already in 2022 with Highbridge deal setup to kill of the company but Capricor managed to overcome and succeeded with the P3 stat sig which set of thier newest scam with the ”pricing flaw” which of course they must of known about all along, if they didn’t then I’m a bit worried we chose amateurs as distributors… they even claim the have everything setup already so how was this critical piece missed by such a large company who claims they have experience in distributing in US market?! NS lost the case with the PLD demand and they are scrambling… Capricor will be just fine without NS and even if we are not scaling up like planned it seems we still in a good position going forward… Linda’s fighting spirit makes me calm over my position.. let’s get it
0 · Reply
braindonor
braindonor May. 19 at 5:54 AM
$CAPR $CAPR here’s a good explanation of what NS was up to and why.
1 · Reply
haha1978
haha1978 May. 19 at 2:40 AM
$CAPR where was that loser short who bought puts before the pop to 40? This will be the same scenario longs with actual shares selling puts to broke shorts only able to buy options.
1 · Reply
quito_yume
quito_yume May. 19 at 1:36 AM
$CAPR We are in the final stages of the countdown boys and girls. Don't be surprised to see big announcements this week or next. Don't try to time this one as it could happen any day now, including as early as tomorrow. The MM's are driving the price down for their friends to be able to get in cheap because they know what's coming as well as we do. GLTA!
1 · Reply
hegdaom
hegdaom May. 19 at 1:24 AM
$CAPR
0 · Reply
Weightgainclyde
Weightgainclyde May. 19 at 12:53 AM
$CAPR I’m curious in what other biostocks my fellow CAPR’s invest in. Aside from capr I’m in cadl SLS and ocgn
15 · Reply
dnfrs
dnfrs May. 18 at 11:37 PM
$CAPR Deramiocel will have a powerful effect on the lives of DMD patients. But Capricor has other tools that could be developed using the StealthX exosome platform. https://doaj.org/article/fc20574b01b046f4b63766549f7f01ee?utm_source=copilot.com
0 · Reply
spacecity777
spacecity777 May. 18 at 10:34 PM
$CAPR I spoke to several notable attorney's over the weekend and they both said recission is almost a given. Both parties will be returned to their precontract position. So Capricor will return the milestone payments and Capricor will get 100% of the product rights back. This is absolutely the best situation of all! I think there is a likelihood that NS agrees to this prior to the June 3rd hearing. This is an absolute grand slam event for Capricor shareholders. Sit tight, good days are coming!
7 · Reply
GhostOfFrankie4Fingers
GhostOfFrankie4Fingers May. 18 at 10:23 PM
$CAPR I lost a lot of respect for Martin when he shorted this one, but he still holds a special place in my heart after I banked on the $SAVA short.
2 · Reply
Dash_Man
Dash_Man May. 18 at 10:18 PM
$CAPR AI review of the NS call.
0 · Reply
hegdaom
hegdaom May. 18 at 9:54 PM
$CAPR
0 · Reply
BioResearcher
BioResearcher May. 18 at 9:40 PM
$CAPR We may see $16 IF NS wins in Court ! But chance of foreign companies in in Court is very low. at this price, Wall Street bet on NS will lose in Court. Let's pray that is the case for the sake of sick kids.
2 · Reply
AFJ3
AFJ3 May. 18 at 9:22 PM
$CAPR it seems like this call confirmed 3 very important legal points for Linda and team: His acknowledgment of the pricing structural flaw. (Mutual mistake) His statement that the current contract “must be modified. (Can’t launch this under current deal) His admission that deramiocel is neutral to NS’s operating profit if it disappears. (Irreparable harm to CAPR but not really detrimental to NS) Aside from that other points imo worth mentioning; CEO mentions PLD isn’t unprecedented cause they did similar deal with another bio company (RegenxBio). Cuts a bit into what Linda said on call but not much since we don’t have details. They expect approval. Final take: Pay back milestone, keep all of US to ourselves and let NS have Japan whenever they get approval out there. NS saves face with their investors and everyone wins.
2 · Reply
Public_Accountant1
Public_Accountant1 May. 18 at 8:24 PM
$CAPR Loading up on August puts. everyone knows martin always has the last laugh
7 · Reply
Schiellerup
Schiellerup May. 18 at 8:15 PM
$CAPR Only 1.7% of the amount of outstanding shares, traded today. Today we just follow the market. If you believe, take advantage of the price
2 · Reply
LouMaglie
LouMaglie May. 18 at 8:10 PM
$CAPR I'm happy to pick up another 100 shares today. Thanks!
0 · Reply
dnfrs
dnfrs May. 18 at 7:52 PM
$CAPR I find quito_yume's model interesting when you project it out a few years. When the US patient size reaches 6,000 the share price would be over a thousand dollars. Add in worldwide sales, Becker, other cardiomyopathies, and StealthX exosome drug delivery and we are looking at a solid 4 digit share price. It won't be long before the FDA approval and new marketing arrangements come. I am long and strong!
0 · Reply
AFJ3
AFJ3 May. 18 at 7:49 PM
$CAPR https://www.nippon-shinyaku.co.jp/file/download.php?file_id=11070 NS had earnings on Friday. For anyone interested in running this through AI to see their side of the story during the Q&A portion. Here’s what I gathered thus far.
5 · Reply
bond1971
bond1971 May. 18 at 7:34 PM
$CAPR don’t get shaken out by the legal proceedings. Short term pain for LONG TERM GAINS . After all the BS short attacks Martin fake thesis . This will be a walk in the park Taking advantage of the dip
0 · Reply
NeLoWtF_
NeLoWtF_ May. 18 at 7:31 PM
$SLS holding $7 like a fortress while we wait for the final 2 deaths. 🏛️🛡️ Those patients are becoming legends! Math says the survival is nuclear. 🧬📈 Meanwhile, $CAPR is giving us a discount at $27. Buying the lawsuit fear before the PDUFA glory. 🛍️🔥 Liquidity ready, shares locked, and feeling HOT. This is how you win the biotech war! 🥂🚀 #SLS #REGAL #CAPR #PDUFA #ShortSqueeze #Event80
0 · Reply
Dash_Man
Dash_Man May. 18 at 7:11 PM
$CAPR I suspect the plunge downward in stock price is being led by retail shorts. The guys who think "they know" this is the beginning of a decline. They could be right. I believe, on the other hand, this drop is a spring being compressed to its absolute limit. The shorts have engineered their own destruction, and they are entirely oblivious to the fact that the fuse is already lit.
2 · Reply
Theobviouschoice
Theobviouschoice May. 18 at 6:30 PM
$CAPR Games being played look at the Trade Volume <500K. Expect recovery very soon🚀🚀🚀
0 · Reply